Clinical Report: Innovative Serum Inflammatory Markers and ISR Post-PCI

Overview

This study investigates the association of novel inflammatory markers and atypical lipid profiles with in-stent restenosis (ISR) following percutaneous coronary intervention (PCI). Key findings indicate that CRI-II and LCI are independent risk factors for ISR.

Background

In-stent restenosis (ISR) remains a significant challenge in the management of coronary heart disease despite advancements in drug-eluting stents (DES). Accurate identification of biomarkers for ISR is crucial, as ISR can lead to recurrent cardiovascular events and necessitate repeated revascularization. Understanding the role of inflammation and lipid metabolism in ISR pathogenesis is essential.

Data Highlights

Key Findings

• Higher levels of SII, SIRI, NLR, PLR, MLR, PIV, CRI-II, and LCI were observed in the ISR group compared to the non-ISR group (all P < 0.05).
• CRI-II was identified as an independent risk factor for ISR with an odds ratio of 1.277 (95% CI: 1.066–1.529, p = 0.008).
• LCI was also an independent risk factor for ISR with an odds ratio of 1.010 (95% CI: 1.002–1.018, p = 0.020).
• ROC analysis indicated CRI-II had an AUC of 0.586 and LCI had an AUC of 0.571.
• No novel serum inflammatory markers were independently associated with ISR in multivariate analysis.

Clinical Implications

The study highlights the need for further research to validate the predictive value of CRI-II and LCI in clinical settings. Clinicians should remain cautious in utilizing these biomarkers for ISR risk stratification until more robust evidence is available.

Conclusion

CRI-II and LCI show statistical associations with ISR after PCI, but their discriminatory ability is limited.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy
2. Frontiers in Cardiovascular Medicine, 2026 -- Residual inflammatory risk post STEMI: high prevalence despite LDL-C control and association with other secondary prevention targets
3. Clinical Research in Cardiology, 2022 -- Myocardial Injury During Procedures Linked to Neointimal Optical Properties and Treatment Approaches for In-Stent Restenosis
4. 2024 ESC Guidelines for the management of chronic coronary syndromes | European Heart Journal
5. Clinical Research in Cardiology — Impact of Coronary No-Reflow on Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention with Modern Drug-Eluting Stents and Third-Generation P2Y12 Inhibitors
6. AGENT Paclitaxel-Coated Balloon Catheter – P230035 | FDA
7. 2024 ESC Guidelines for the management of chronic coronary syndromes | European Heart Journal | Oxford Academic
8. Neutrophil-to-lymphocyte ratio as a potential biomarker in predicting in-stent restenosis: A systematic review and meta-analysis - PMC